High Levels of Timp-2 Correlate with Adverse Prognosis in Breast Cancer

[en] TIMP-2 is an endogenous inhibitor of MMPs. Most data from model systems suggest that high levels of this inhibitor prevent metastasis. In human breast cancers, however, we show that high levels of TIMP-2 correlate with both shortened disease-free interval and overall survival. In primary breast cancers, TIMP-2 levels showed no significant relationship with either tumor size or axillary node status but correlated inversely with estrogen receptor levels. TIMP-2 levels also correlated significantly with those for TIMP-1. We conclude that high levels of endogenous TIMP-2, like other protease inhibitors such as PAI-1 and TIMP-1, correlate with progression of human breast cancer.

Disciplines :

Anatomy (cytology, histology, embryology...) & physiology

Author, co-author :

Remacle, A.

McCarthy, K.

Noël, Agnès ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme

Maguire, T.

McDermott, E.

O'Higgins, N.

Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique

Duffy, M. J.

Language :

English

Title :

High Levels of Timp-2 Correlate with Adverse Prognosis in Breast Cancer

Publication date :

20 March 2000

Journal title :

International Journal of Cancer

ISSN :

0020-7136

eISSN :

1097-0215

Publisher :

Wiley Liss, Inc., New York, United States - New York

Volume :

Issue :

Pages :

118-21

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 21 August 2009

Statistics

Number of views

70 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

101

Scopus citations^®
without self-citations

OpenCitations

Bibliography

ANDREASEN, P., KJOLLER, L., CHRISTENSEN, L. and DUFFY, M.J., The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer, 72, 1-22 (1997).
BAFETTI, L.M., YOUNG, T.N., ITOH, Y. and STACK, M.S., Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and enhanced cellular invasion by melanoma cells. J. Biol. Chem., 273, 143-149 (1998).
BAJOU, K., NOËL, A., GERARD, R., MASSON, V., BRUNNER, N., HOLST-HANSEN, C., SKOBE, M., FUSENIG, N.E., CARMELIET, P., COLLEN, D. and FOIDART, J.M., Absence of plasminogen activator-1 prevents cancer invasion and vascularization. Nature (Med.), 4, 923-928 (1998).
CHAMBERS, A.F. and MATRISIAN, L.M., Changing views of the role of matrix metalloproteinases in metastasis. J. nat. Cancer Inst., 89, 1260-1270 (1991).
CORCORAN, M.L. and STETLER-STEVENSON, W.O., Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J. biol. Chem., 270, 13453-13459 (1995).
CROFFORD, L.J., SANO, H., KARALIS, K., FRIEDMAN, T.C., EPPS, H.R., REMMERS, E.F., MATHERN, P., CHROUSOS, G.P. and WILDER, R.L., Corticotropin-releasing hormone in synovial fluids and tissue of patients with rheumatoid arthritis and osteoarthritis. J. Immunol., 151, 1587-1596 (1993).
DECLERCK, Y. and IMREN, S., Protease inhibitors: role and potential therapeutic use in human cancer. Europ. J. Cancer, 14, 2170-2180 (1994).
DECLERCK, Y.A., PEREZ, N., SHIMADA, H., BOONE, T.C., LANGLEY, K.E. and TAYLOR, S.M., Inhibition of invasion and metastasis in cells transfectcd with an inhibitor of metalloproteinases. Cancer Res., 52, 701-708 (1992).
DOCHERTY, A.J.P., LYONS, A., SMITH, B.J., WRIGHT, E.M., STEPHENS, P.E., HARRIS, T.J.R., MURPHY, G. and REYNOLDS, J.J., Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid potentiating activity. Nature (Lond.), 318, 65-69 (1985).
DUFFY, M.J., BLASER, J., DUGGAN, C., MCDERMOTT, E., O'HIGGINS, N., FENNELLY, J.J. and TSCHESCHE, H., Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer. Brit. J. Cancer. 71, 1025-1028 (1995).
DUFFY, M.J. and MCCARTHY, K., Matrix metalloproteinases in cancer; prognostic markers and targets for therapy. Int. J. Oncol., 12, 1343-1348 (1998).
DUFFY, M.J., O'SIORAIN, L., WALDRON, B. and SMITH, C., Estradiol receptors in human breast carcinomas assayed by use of monoclonal antibodies. Clin. Chem., 32, 1972-1974 (1986).
FABUNMI, R.P., BAKER, A.H., MURRAY, E.J., BOOTH, R.F.G. and NEWBY, A.C., Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2 and -3 in rabbit aortic smooth muscle cells. Biochem. J., 315, 335-342 (1996).
GOMEZ, D.E., ALONSO, D.F., YOSHIJI, H, and THORGEIRSSON, U.P., Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Europ. J. Cell Biol., 74, 111-122 (1997).
GRIGNON, D.J., SAKR, W., TOTH, M., RAVERY, V., ANGULO, J., SHAMSA, F., PONTES, J.E., CRISSMAN, J.C. and FRIDMAN, R., High levels of tissue inhibitor of metalloproteinases-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res., 56, 1654-1659 (1996).
GUEDEZ, L., LIM, M.S. and STETLER-STEVENSON, W.G., The role of metalloproteinases and their inhibitors in hematological disorders. Crit. Rev. Oncol., 7, 205-225 (1996).
GUEDEZ, L., STETLER-STEVENSON, W.G., WOLFF, L., WANG, J., FUKUSHIMA, P., MANSOOR A. and STETLER-STEVENSON, M., In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinase-1. J. clin. Invest., 102, 2002-2010 (1998).
IMREN, S., KOHN, D.B., SHIMADA, H., BLAVIER, L. and DECLERCK, Y.A., Overexpression of tissue inhibitor of metalloproteinase-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res., 56, 2891-2895 (1996).
JENSENIUS, J., ANDERSEN, I., HAU, J., CRONE, M. and KOCH, C., Eggs: conveniently packaged antibodies. Methods for purification of yolk IgG. J. immunol. Methods, 46, 63-68 (1981).
KANAYAMA, H., YOKOTA, K., KUROKAWA, Y., NISHITANI, M. and KAGAWA, S., Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer, 82, 1359-1366 (1998).
KAWAMATA, H., KAWAI, K., KAMEYAMA, S., JOHNSON, M.D., STETLER-STEVENSON, W.G. and OYASU, R., Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP-1 and TIMP-2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Int. J. Cancer, 63, 680-687 (1995).
MCCARTHY, K., MAGUIRE, T., MCGREAL, G., MCDERMOTT, E., O'HIGGINS, N. and DUFFY, M.J., High levels of TIMP-1 predict poor outcome in patients with breast cancer. Int. J. Cancer, 84, 44-48 (1999).
NAGASE, H., Cell surface activation of progelatinase A (proMMP-2) and cell migration. Cell Res., 8, 179-186 (1998).
NOËL, A., GILLES, C., BAJOU, K., DEVY, L., KEBERS, F., LEWALLE, J.M., MAQUOI, E., MUNAUT, C., REMACLE, A. and FOIDART, J.M., Emerging roles for proteinases in cancer. Invasion Metastasis, 17, 221-239 (1997).
NOËL, A., HAJITOU, A., L'HOIR, C., MAQUOI, E., BARAMOVA, E., LEWALLE, J.M., REMACLE, A., KEBERS, F., BROWN, P., CALBERG-BACQ, C.M. and FOIDART, J.M., Inhibition of stromal matrix metalloproteinases: effects on breast tumor promotion by fibroblasts. Int. J. Cancer, 76, 1-7 (1998).
REE, A.H., FLYRENES, V.A., BERG, J.P., MAELANDSMO, G.M., NESLAND, J.M. and FODSTAD, Y., High levels of mRNA for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of metastases. Clin. Cancer Res., 3, 1623-1628 (1997).
REILLY, D., CHRISTENSEN, L., DUCH, M., NOLAN, N., DUFFY, M.J. and ANDREASEN, P.A., Type-1 plasminogen activator inhibitor in human breast carcinomas. Int. J. Cancer, 50, 208-214 (1992).
STETLER-STEVENSON, W.G., BERSCH, N. and GOLDE, D.W., Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett., 296, 231-234 (1992).
STETLER-STEVENSON, W.G., BROWN, P.D., ONISTO, M., LEVY, A.T. and LIOTTA, L.A., Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J. biol. Chem., 265, 13933-13938 (1990).
STRONGIN, A.Y., COLLIER, I., BANNIKOV, G., MARMER, B.L., GRANT, G.A. and GOLDBERG, G.I., Mechanism of cell surface activation of 72-kDa type IV collagenase. J. biol. Chem., 270, 5331-5338 (1995).
VISSCHER, D.W., HOYHTYA, M., OTTOSEM, S.K., LIANG, C.M., SARKAR, F.H., CRISSMAN, J.D. and FRIDMAN, R., Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int. J. Cancer, 59, 339-344 (1994).
ZUCKER, S., MIRZA, H., CONNER, C.E., LORENZ, A.F., DREWS, M.H., BAHOU, W.F. and JESTY, J., Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells; conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int. J. Cancer, 75, 780-786 (1998).